Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenerative Medical Technology (RMTG) EBT (2018 - 2025)

Historic EBT for Regenerative Medical Technology (RMTG) over the last 8 years, with Q3 2025 value amounting to -$3.9 million.

  • Regenerative Medical Technology's EBT fell 34436.35% to -$3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.6 million, marking a year-over-year increase of 73.94%. This contributed to the annual value of -$5.6 million for FY2024, which is 2284.43% up from last year.
  • Regenerative Medical Technology's EBT amounted to -$3.9 million in Q3 2025, which was down 34436.35% from -$1.3 million recorded in Q2 2025.
  • Regenerative Medical Technology's 5-year EBT high stood at -$74211.0 for Q1 2023, and its period low was -$9.9 million during Q3 2021.
  • Its 5-year average for EBT is -$1.9 million, with a median of -$1.5 million in 2022.
  • Per our database at Business Quant, Regenerative Medical Technology's EBT soared by 9559.03% in 2023 and then tumbled by 254047.38% in 2024.
  • Regenerative Medical Technology's EBT (Quarter) stood at -$1.6 million in 2021, then tumbled by 57.39% to -$2.5 million in 2022, then rose by 28.04% to -$1.8 million in 2023, then soared by 63.86% to -$639071.0 in 2024, then crashed by 516.01% to -$3.9 million in 2025.
  • Its EBT was -$3.9 million in Q3 2025, compared to -$1.3 million in Q2 2025 and -$758890.0 in Q1 2025.